NASDAQ:MXCT MaxCyte (MXCT) Stock Price, News & Analysis $4.79 +0.17 (+3.68%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.53▼$4.8350-Day Range$3.68▼$5.0652-Week Range$2.45▼$5.55Volume493,100 shsAverage Volume592,188 shsMarket Capitalization$502.09 millionP/E RatioN/ADividend YieldN/APrice Target$8.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MaxCyte alerts: Email Address MaxCyte MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.9% Upside$8.67 Price TargetShort InterestBearish4.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 3 Articles This WeekInsider TradingAcquiring Shares$489,113 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.50) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.68 out of 5 starsMedical Sector484th out of 936 stocksCommercial Physical Research Industry6th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingMaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMaxCyte has received no research coverage in the past 90 days.Read more about MaxCyte's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.57% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in MaxCyte has recently increased by 2.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MXCT. Previous Next 2.5 News and Social Media Coverage News SentimentMaxCyte has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MaxCyte this week, compared to 1 article on an average week.MarketBeat Follows2 people have added MaxCyte to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have bought 111.96% more of their company's stock than they have sold. Specifically, they have bought $489,113.00 in company stock and sold $230,762.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of MaxCyte is held by insiders.Percentage Held by Institutions68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MaxCyte's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MaxCyte are expected to grow in the coming year, from ($0.50) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MaxCyte is -13.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MaxCyte is -13.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MaxCyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About MaxCyte Stock (NASDAQ:MXCT)MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More MXCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MXCT Stock News HeadlinesJuly 11, 2024 | insidertrades.comMaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross Sells 13,531 SharesJuly 3, 2024 | insidertrades.comMaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 10,000 SharesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 20, 2024 | finance.yahoo.comMXCT Oct 2024 2.500 put (MXCT241018P00002500)July 20, 2024 | finance.yahoo.comMXCT Aug 2024 2.500 put (MXCT240816P00002500)July 9, 2024 | globenewswire.comMaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024May 29, 2024 | globenewswire.comMaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceMay 22, 2024 | globenewswire.comMaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 8, 2024 | lse.co.ukMaxCyte shares rise amid double-digit revenue increaseMay 8, 2024 | finance.yahoo.comMaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...May 7, 2024 | investorplace.comMXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceMay 7, 2024 | globenewswire.comMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceMay 3, 2024 | morningstar.comMaxCyte Inc MYE0April 26, 2024 | finance.yahoo.comMaxCyte, Inc. (MXCT)April 10, 2024 | globenewswire.comMaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024April 5, 2024 | msn.comMesa Laboratories maintains quarterly dividend of $0.16See More Headlines Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:MXCT CUSIPN/A CIK1287098 Webmaxcyte.com Phone301-944-1700Fax301-944-1703Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$11.00 Low Stock Price Target$7.00 Potential Upside/Downside+80.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,920,000.00 Net Margins-83.00% Pretax Margin-83.00% Return on Equity-15.68% Return on Assets-13.74% Debt Debt-to-Equity RatioN/A Current Ratio13.26 Quick Ratio12.37 Sales & Book Value Annual Sales$41.29 million Price / Sales12.16 Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book2.15Miscellaneous Outstanding Shares104,820,000Free Float101,679,000Market Cap$502.09 million OptionableOptionable Beta1.41 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Douglas Arthur Doerfler (Age 68)Founder Comp: $2.34MMr. Douglas J. Swirsky CFA (Age 55)CPA, Chief Financial Officer Comp: $607.42kMr. Jay GelfmanSenior Vice President of OperationsMr. Ronald Evan Holtz CPA (Age 66)Ph.D., Executive Vice President of Administration Comp: $649.38kKey CompetitorsHeron TherapeuticsNASDAQ:HRTXMacroGenicsNASDAQ:MGNXMeiraGTxNASDAQ:MGTXArcturus TherapeuticsNASDAQ:ARCTHarvard BioscienceNASDAQ:HBIOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 83,025 shares on 7/26/2024Ownership: 0.404%Chevy Chase Trust Holdings LLCBought 26,163 shares on 7/22/2024Ownership: 1.262%SG Americas Securities LLCSold 11,194 shares on 7/12/2024Ownership: 0.020%Thomas M RossSold 13,531 sharesTotal: $54,529.93 ($4.03/share)John Joseph JohnstonSold 10,000 sharesTotal: $39,900.00 ($3.99/share)View All Insider TransactionsView All Institutional Transactions MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at $4.70 on January 1st, 2024. Since then, MXCT shares have increased by 1.9% and is now trading at $4.79. View the best growth stocks for 2024 here. How were MaxCyte's earnings last quarter? MaxCyte, Inc. (NASDAQ:MXCT) announced its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.05. The firm earned $11.34 million during the quarter, compared to analyst estimates of $7.75 million. MaxCyte had a negative net margin of 83.00% and a negative trailing twelve-month return on equity of 15.68%. When did MaxCyte IPO? MaxCyte (MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share. Who are MaxCyte's major shareholders? Top institutional shareholders of MaxCyte include Chevy Chase Trust Holdings LLC (1.26%), Bank of New York Mellon Corp (0.40%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Maher Masoud, Richard Douglas and Thomas M Ross. View institutional ownership trends. How do I buy shares of MaxCyte? Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MXCT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
